BBVA vs IBKR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BBVA's Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 3/9, signaling significant operational and balance sheet concerns. Despite this, the bank trades at a reasonable valuation with a P/E of 12.30 below the sector average of 21.13, and offers a solid 3.31% dividend yield supported by a sustainable 39.86% payout ratio. Profitability metrics like a 32.91% profit margin and 18.63% ROE are strong, but negative earnings growth and poor technical trend (10/100) offset these gains. The absence of Altman Z-Score data prevents a full distress risk assessment, but the low Piotroski score demands caution.
IBKR demonstrates stable financial health with a Piotroski F-Score of 6/9 and exceptional operating margins of 78.8%. While the company shows robust growth with 30.3% YoY earnings increases and a strong ROE of 23.51%, it is trading at a significant premium to both its Graham Number ($24.52) and Intrinsic Value ($65.49). This valuation gap is further highlighted by a high PEG ratio of 2.90 and a current price ($81.25) that exceeds the analyst target price ($78.30). Bearish insider selling and a weak technical trend (10/100) suggest the stock may be overextended despite its fundamental strength.
Compare Another Pair
Related Comparisons
BBVA vs IBKR: Head-to-Head Comparison
This page compares Banco Bilbao Vizcaya Argentaria, S.A. (BBVA) and Interactive Brokers Group, Inc. (IBKR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.